Aplastic Anaemia Pipeline Analysis 2019 (H1)

Aplastic Anaemia Pipeline Analysis report covers 8 drugs currently in different phases of development. Aplastic Anaemia is a rare, serious condition which occurs when bone marrow fails to produce enough new cells. Symptoms of aplastic anaemia are fatigue, breathlessness or shortness of breath, irregular or rapid heartbeat, frequent bleeding from nose and gums, prolonged or uncontrolled bleeding from cuts and wounds, skin rash, dizziness, and headache. Aplastic anaemia occurs as a result of damage to the bone marrow due to radiation or chemotherapy treatments, exposure to toxic chemicals, certain autoimmune disorders or various other factors. Diagnosis is done by blood tests and bone marrow biopsy. Preferred treatment options for aplastic anemia are blood transfusions and bone marrow transplant.

The report provides Aplastic Anaemia treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing, and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining a faster and efficient understanding of the market.

Major industry players profiled as part of the report are, Hemogenyx Pharmaceuticals PLC, Amgen and Pluristem Therapeutics Inc. among others.

Scope:

By Company
By Phase
By Molecule Type
By Region
By Route of Administration

1. Introduction

1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region

2. Disease Overview

2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology

3. Executive Summary

4. Market Dynamics

4.1. Drivers
4.2. Restraints
4.3. Opportunities

5. Pipeline Analysis/Outlook

5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling

Drug Name
Generic Name
Synonyms
Company
Collaborator
Route of administration
Target
Mechanism of Action
Technology
Molecule type
CAS Number
Weight
Chemical Formula
IUPAC name
ATC code

5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region

6. Company profiling

6.1. 3 SBio Group
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.1.5. Recent Developments
6.2. Amgen
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.2.5. Recent Developments
6.3. BioLineRx
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.3.5. Recent Developments
6.4. Cellenkos Inc.
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.4.5. Recent Developments
6.5. Gamida Cell
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.5.5. Recent Developments
6.6. Hemogenyx Pharmaceuticals PLC
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.6.5. Recent Developments
6.7. Kyowa-Hakko Kirin
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.7.5. Recent Developments
6.8. Pluristem Therapeutics Inc.
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.8.5. Recent Developments
6.9. Jiangsu HengRui Medicine Co., Ltd.
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.9.5. Recent Developments
6.10. Regen BioPharma
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT
6.10.5. Recent Developments